Diving Deeper into Biogen's Lingo Results
Biogen's nerve repair drug failed to clear some key hurdles in its clinical trial against an eye disease. But the company highlighted positive data that shows the drug could have potential in its much more important target, multiple sclerosis.
3 Value Stocks Near 52-Week Lows Worth Buying
These three value stocks may have been pummeled in recent weeks, but they may not stay near their 52-week lows for much longer.